Laboratory of Experimental Hematology and Stem Cells, Institute for Medical Research, University of Belgrade, Belgrade, Serbia.
Laboratory for Immunochemistry, Institute for Medical Research, University of Belgrade, Belgrade, Serbia.
Dev Dyn. 2022 Jan;251(1):105-124. doi: 10.1002/dvdy.339. Epub 2021 Apr 8.
Transforming growth factor-beta1 (TGF-β1) plays a crucial role in tumor progression. It can inhibit early cancer stages but promotes tumor growth and development at the late stages of tumorigenesis. TGF-β1 has a potent immunosuppressive function within the tumor microenvironment that largely contributes to tumor cells' immune escape and reduction in cancer immunotherapy responses. Likewise, myeloid-derived suppressor cells (MDSCs) have been postulated as leading tumor promoters and a hallmark of cancer immune evasion mechanisms. This review attempts to analyze the prominent roles of both TGF-β1 and MDSCs and their interplay in cancer immunity. Furthermore, therapies against either TGF-β1 or MDSCs, and their potential synergistic combination with immunotherapies are discussed. Simultaneous TGF-β1 and MDSCs inhibition suggest a potential improvement in immunotherapy or subverted tumor immune resistance.
转化生长因子-β1（TGF-β1）在肿瘤进展中起着至关重要的作用。它可以抑制早期癌症阶段，但在肿瘤发生的晚期促进肿瘤生长和发展。TGF-β1 在肿瘤微环境中具有强大的免疫抑制功能，这在很大程度上导致肿瘤细胞的免疫逃逸和癌症免疫治疗反应的减少。同样，髓源抑制细胞（MDSCs）被认为是主要的肿瘤促进剂和癌症免疫逃逸机制的标志。本综述试图分析 TGF-β1 和 MDSCs 的突出作用及其在癌症免疫中的相互作用。此外，还讨论了针对 TGF-β1 或 MDSCs 的治疗方法，以及它们与免疫疗法的潜在协同组合。同时抑制 TGF-β1 和 MDSCs 可能会改善免疫治疗或改变肿瘤的免疫抵抗。
